论文部分内容阅读
本研究旨在通过流式细胞术标记CD25,探讨其与急性B淋巴细胞白血病(B-ALL)的关系及其临床意义。选择88例初发B-ALL患者骨髓,应用流式细胞术检测免疫表型标记,包括白介素2受体α链(CD25)、β链(CD122)、γ链(CD132),CD19、CD20、CD10、CD34、CDIgM、CD79a、CD22、CDTDT;用定性PCR方法检测BCR/ABL融合基因表达,实时定量PCR检测IL2RA(CD25基因)的表达。结果表明,CD25+和CD25-的B-ALL患者白细胞计数(WBC)、血红蛋白(Hb)、血小板(Plt)、骨髓原始细胞比例(marrow blast%)、外周血原始细胞比例(peripheral blast%)、肝脾和淋巴结肿大、CD10、CD20、CD22、CD34、CD79a、CDTDT、CDIgM表达水平差别均无统计学意义(P>0.05),而CD19在CD25+组中表达水平高于CD25-组(P<0.05)。本组BCR/ABL+患者为21例(23.9%,21/88),CD25+表达率为66.7%(14/21);BCR/ABL-患者为67例,CD25+表达率为4.5%(3/67),两组间差别有统计学意义(P<0.05)。IL2RA基因mRNA表达水平在CD25+和CD25-两组间无统计学差异(P>0.05)。21例BCR/ABL+B-ALL患者中,CD25+与CD25-两组间在缓解率和复发率方面差异无统计学意义(P>0.05)。BCR/ABL+B-ALL患者中有8例复发,复发率为38.1%(8/21),BCR/ABL-组有9例复发,复发率为13.4%(9/67),两组间差异有统计学意义(P<0.05)。BCR/ABL+组无复发生存时间(relapse-free survival,RFS)为21个月,BCR/ABL+CD25+患者RFS时间为15个月,而BCR/ABL+CD25-患者RFS时间为21个月,BCR/ABLCD25-患者RFS时间为24个月。结论:CD25在BCR/ABL+B-ALL患者中呈高水平表达,可以作为B-ALL的BCR/ABL融合基因表达的预测指标,与疾病复发有关,CD25+可以作为判断B-ALL不良预后的辅助标志。
The purpose of this study was to identify the relationship between CD25 and acute B-lymphocytic leukemia (B-ALL) by flow cytometry and its clinical significance. The bone marrow of 88 patients with newly diagnosed B-ALL were selected and the immunophenotypic markers were detected by flow cytometry, including interleukin 2 receptor alpha chain (CD25), beta chain (CD122), gamma chain (CD132), CD19, CD20, CD10 , CD34, CDIgM, CD79a, CD22, CDTDT; Detection of BCR/ABL fusion gene expression by qualitative PCR method, real-time quantitative PCR detection of IL2RA (CD25 gene) expression. The results showed that white blood cell count (WBC), hemoglobin (Hb), platelet (Plt), marrow blast%, peripheral blast%, liver of patients with B-ALL with CD25+ and CD25- There was no significant difference in spleen and lymph node enlargement, CD10, CD20, CD22, CD34, CD79a, CDTDT, and CDIgM expression levels (P>0.05), while CD19 expression was higher in the CD25+ group than in the CD25-group (P<0.05). ). The patients with BCR/ABL+ were 21 (23.9%, 21/88), the CD25+ expression rate was 66.7% (14/21), the BCR/ABL- patients were 67, and the CD25+ expression rate was 4.5% (3/67). There was a statistically significant difference between the two groups (P<0.05). There was no significant difference in IL2RA mRNA expression levels between CD25+ and CD25- groups (P>0.05). In 21 patients with BCR/ABL+B-ALL, there was no significant difference in remission rate and recurrence rate between CD25+ and CD25- groups (P>0.05). Eight patients with BCR/ABL+B-ALL had recurrence, the recurrence rate was 38.1% (8/21), and 9 patients in the BCR/ABL-group had recurrence with a recurrence rate of 13.4% (9/67). Statistically significant (P<0.05). The relapse-free survival (RFS) of the BCR/ABL+ group was 21 months, the RFS of the BCR/ABL+CD25+ patient was 15 months, and the RFS of the BCR/ABL+CD25-patient was 21 months. /ABLCD25-patient RFS time is 24 months. Conclusion: CD25 is highly expressed in BCR/ABL+B-ALL patients and can be used as a predictor of BCR/ABL fusion gene expression in B-ALL and is associated with disease recurrence. CD25+ can be used as an aid to determine the poor prognosis of B-ALL. Sign.